PPC
JAZZ icon

Park Place Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Park Place Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.1K Sell
96
-8
-8% -$1.4K ﹤0.01% 504
2025
Q4 		$17.7K Sell
104
-5
-5% -$767 ﹤0.01% 476
2025
Q3 		$14.4K Buy
109
+13
+14% +$1.56K ﹤0.01% 499
2025
Q2 		$10.5K Hold
96
– – ﹤0.01% 578
2025
Q1 		$11.9K Buy
96
+83
+638% +$10.8K ﹤0.01% 546
2024
Q4 		$1.6K Hold
13
– – ﹤0.01% 751
2024
Q3 		$1.45K Sell
13
-60
-82% -$6.58K ﹤0.01% 805
2024
Q2 		$7.79K Sell
73
-21
-22% -$2.31K ﹤0.01% 647
2024
Q1 		$11.3K Sell
94
-3
-3% -$367 ﹤0.01% 627
2023
Q4 		$11.9K Buy
97
+8
+9% +$998 ﹤0.01% 603
2023
Q3 		$11.5K Hold
89
– – ﹤0.01% 735
2023
Q2 		$11K Hold
89
– – ﹤0.01% 756
2023
Q1 		$13K Sell
89
-11
-11% -$1.63K ﹤0.01% 715
2022
Q4 		$16K Buy
+100
New +$14.7K ﹤0.01% 691

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Park Place Capital's JAZZ Position: Q1 2026 in Review

Park Place Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 7.7% in Q1 2026, selling an estimated $1.4K and leaving 96 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #504.

Park Place Capital first reported a position in JAZZ in Q4 2022 and has held it in 14 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Park Place Capital held 96 shares of Jazz Pharmaceuticals worth $18.1K as of Q1 2026.
  • Park Place Capital sold 8 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.4K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Park Place Capital's portfolio in Q1 2026, its #504 holding.
  • Park Place Capital first reported a position in Jazz Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Park Place Capital's 13F filing for Q1 2026, filed 9 Apr 2026.